The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.

Abstract

INTRODUCTION:

We aimed to evaluate the treatment sequence for patients with metastatic castration-resistant prostate cancer (mCRPC) in real-world practice and compare overall survival in each sequential therapy.

PATIENTS AND METHODS:

We retrospectively evaluated 146 patients with mCRPC who were initially treated with androgen deprivation therapy as metastatic hormone-naive prostate cancer in 14 hospitals between January 2010 and March 2019. The agents for the sequential therapy included new androgen receptor-targeted agents (ART: abiraterone acetate or enzalutamide), docetaxel, and/or cabazitaxel. We evaluated the treatment sequence for mCRPC and the effect of sequence patterns on overall survival.

RESULTS:

The median age was 71 years. A total of 35 patients received ART-ART, 33 received ART-docetaxel, 68 received docetaxel-ART, and 10 received docetaxel-cabazitaxel sequences. The most prescribed treatment sequence was docetaxel-ART (47%), followed by ART-ART (24%). Overall survival calculated from the initial diagnosis reached 83, 57, 79, and 37 months in the ART-ART, ART-docetaxel, docetaxel-ART, and docetaxel-cabazitaxel, respectively. Multivariate Cox regression analyses showed no significant difference in overall survival between the first-line ART (n = 68) and first-line docetaxel (n = 78) therapies (hazard ratio [HR], 0.84; P = .530), between the ART-ART (n = 35) and docetaxel-mixed (n = 111) sequences (HR, 0.82; P = .650), and between the first-line abiraterone (n = 32) and first-line enzalutamide (n = 36) sequences (HR, 1.58; P = .384).

CONCLUSION:

The most prescribed treatment sequence was docetaxel followed by ART. No significant difference was observed in overall survival among the treatment sequences in real-world practice.

• Authors: Kazutaka Okita, Shingo Hatakeyama, Shintaro Narita, Masahiro Takahashi, Toshihiko Sakurai, Sadafumi Kawamura, Senji Hoshi, Masanori Ishida, Toshiaki Kawaguchi, Shigeto Ishidoya, Jiro Shimoda, Hiromi Sato, Koji Mitsuzuka, Akihiro Ito, Norihiko Tsuchiya, Yoichi Arai, Tomonori Habuchi, Chikara Ohyama
• Journal: Clinical genitourinary cancer (Clin Genitourin Cancer) Vol. 18 Issue 2 Pg. e103-e111 (04 2020) ISSN: 1938-0682 [Electronic] United States
• PMID: 31810867 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2019 Elsevier Inc. All rights reserved.

Chemical References

• Androgen Receptor Antagonists
• Benzamides
• Nitriles
• Taxoids
• Docetaxel
• Phenylthiohydantoin
• cabazitaxel
• enzalutamide
• KLK3 protein, human
• Kallikreins
• Prostate-Specific Antigen
• Abiraterone Acetate

Topics

• Abiraterone Acetate (therapeutic use)
• Aged
• Androgen Receptor Antagonists (pharmacology, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (antagonists & inhibitors, pharmacology, therapeutic use)
• Benzamides
• Docetaxel (therapeutic use)
• Follow-Up Studies
• Humans
• Kallikreins (blood)
• Kaplan-Meier Estimate
• Male
• Nitriles
• Phenylthiohydantoin (analogs & derivatives, therapeutic use)
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms, Castration-Resistant (blood, drug therapy, mortality)
• Retrospective Studies
• Taxoids (therapeutic use)
• Treatment Outcome